Authors
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLCJanuary 29, 2021 - The combination of pembrolizumab plus concurrent chemoradiation therapy showed antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer, regardless of PD-L1 status or tumor histology.
Latest:
Dr Hassan on the CHRYSALIS trial of Amivantamab in EGFR Exon 20–Mutated NSCLCKhaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.
Latest:
Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung AdenocarcinomaKhaled A. Tolba, MD, MBBCh, discusses the use of afatinib in NRG1 fusion–positive lung adenocarcinoma.
Latest:
Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual MeetingsShared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.
Latest:
Dr. Salerno Discusses Hypofractionation for Early Breast CancerKilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.
Latest:
Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid TumorsKim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.
Latest:
Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPCKim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.
Latest:
Is Our Healthcare System Ready to Integrate Cancer Care?In response to the billions of dollars wasted each year in the United States on fragmented, ineffective, and uncoordinated care, some healthcare reform efforts have focused on integrating the delivery of healthcare.
Latest:
Kim Kelly on Clinical Practice Guidelines for MucositisKim Kelly, from John Theurer Cancer Center, on the Updated MASCC/ISOO Clinical Practice Guidelines for Mucositis
Latest:
Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate CancerKim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Latest:
Dr. Van Zee on Nomograms for Patients With DCISKimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).
Latest:
Dr. Blackwell on the Treatment of Young Women With Breast CancerKimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.
Latest:
Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain MetastasesKimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.
Latest:
Dr. Corbin on Patient Selection for Proton Therapy in Breast CancerKimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.
Latest:
Dr. Van Zee on Prevention of Invasive Recurrence in Breast CancerKimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.
Latest:
Dr Ng on Treatment Considerations for Younger Patients With CRCKimmie Ng, MD, MPH, discusses treatment considerations for younger patients with colorectal cancer.
Latest:
Dr. Turaga on Surgery Versus Immunotherapy in MelanomaKiran K. Turaga, MD, associate professor of surgery, vice chief, section of general surgery and surgical oncology, director of the Surgical GI Cancer Program and the Regional Therapeutics Program at The University of Chicago Medicine, discusses whether patients vie for immunotherapy versus surgery as treatment for their melanoma.
Latest:
Dr. Turaga Discusses Current Surgical Setting of SarcomaKiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.
Latest:
Klaus Hoeflich on Treatment Challenges With Liver CancerKlaus Hoeflich, PhD, director of Biology, Blueprint Medicines, discusses diagnosis of liver cancer as well as the treatment challenges associated with the disease during the 10th Annual Conference of the International Liver Cancer Association in Vancouver, Canada.
Latest:
Updates on Multiple Myeloma Diagnosis and Treatment StrategiesProgress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.
Latest:
Dr. Fertrin on the Potential of Fostamatinib in Chronic ITPKleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).
Latest:
Dr. van Besien on Autologous Stem Cell Transplantation in Hematologic MalignanciesKoen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.
Latest:
Dr Shitara on the Background of the CheckMate 649 Trial in GEJ AdenocarcinomaKohei Shitara, MD, discusses the background of the phase 3 CheckMate 649 study in advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma.
